Speakers: Ravi Srinivasan and Andrew Clark, partners at J A Kemp
Recent cases show that both the UK courts and the EPO Boards of Appeal are taking an increasingly strict approach in requiring a plausible disclosure of efficacy in the specification as filed when assessing claims involving pharmaceutical products (both small and large molecules). All those working in the pharmaceutical field ought to have a clear and up to date understanding of legal developments in this area. We will walk through the key UK and EPO cases in this area, and also spend some time discussion how these legal developments should affect our drafting practice.
If you are overseas and would like to book onto this webinar, please email email@example.com to ensure that you receive a Non-VAT invoice.